Current and emerging treatment strategies for Duchenne muscular dystrophy
Jean K Mah Department of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Abstract: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to...
Saved in:
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-07-01
|
| Series: | Neuropsychiatric Disease and Treatment |
| Subjects: | |
| Online Access: | https://www.dovepress.com/current-and-emerging-treatment-strategies-for-duchenne-muscular-dystro-peer-reviewed-fulltext-article-NDT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850157147568996352 |
|---|---|
| author | Mah J |
| author_facet | Mah J |
| author_sort | Mah J |
| collection | DOAJ |
| description | Jean K Mah Department of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Abstract: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. The diagnosis can usually be made after careful review of the history and examination of affected boys presenting with developmental delay, proximal weakness, and elevated serum creatine kinase, plus confirmation by muscle biopsy or genetic testing. Precise characterization of the DMD mutation is important for genetic counseling and individualized treatment. Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. New emerging treatment includes viral-mediated microdystrophin gene replacement, exon skipping to restore the reading frame, and nonsense suppression therapy to allow translation and production of a modified dystrophin protein. Other potential therapeutic targets involve upregulation of compensatory proteins, reduction of the inflammatory cascade, and enhancement of muscle regeneration. So far, data from DMD clinical trials have shown limited success in delaying disease progression; unforeseen obstacles included immune response against the generated mini-dystrophin, inconsistent evidence of dystrophin production in muscle biopsies, and failure to demonstrate a significant improvement in the primary outcome measure, as defined by the 6-minute walk test in some studies. The long-term safety and efficacy of emerging treatments will depend on the selection of appropriate clinical end points and sensitive biomarkers to detect meaningful changes in disease progression. Correction of the underlying mutations using new gene-editing technologies and corticosteroid analogs with better safety profiles offers renewed hope for many individuals with DMD and their families. Keywords: Duchenne muscular dystrophy, emerging treatment, standard of care, review  |
| format | Article |
| id | doaj-art-0fdd89a576fd45eeb45491b46e3ac0df |
| institution | OA Journals |
| issn | 1178-2021 |
| language | English |
| publishDate | 2016-07-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Neuropsychiatric Disease and Treatment |
| spelling | doaj-art-0fdd89a576fd45eeb45491b46e3ac0df2025-08-20T02:24:15ZengDove Medical PressNeuropsychiatric Disease and Treatment1178-20212016-07-01Volume 12Issue 11795180728026Current and emerging treatment strategies for Duchenne muscular dystrophyMah J0Department of Pediatrics and Clinical Neurosciences, Cumming School of Medicine,Jean K Mah Department of Pediatrics and Clinical Neurosciences, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada Abstract: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood. It is caused by mutations of the DMD gene, leading to progressive muscle weakness, loss of independent ambulation by early teens, and premature death due to cardiorespiratory complications. The diagnosis can usually be made after careful review of the history and examination of affected boys presenting with developmental delay, proximal weakness, and elevated serum creatine kinase, plus confirmation by muscle biopsy or genetic testing. Precise characterization of the DMD mutation is important for genetic counseling and individualized treatment. Current standard of care includes the use of corticosteroids to prolong ambulation and to delay the onset of secondary complications. Early use of cardioprotective agents, noninvasive positive pressure ventilation, and other supportive strategies has improved the life expectancy and health-related quality of life for many young adults with DMD. New emerging treatment includes viral-mediated microdystrophin gene replacement, exon skipping to restore the reading frame, and nonsense suppression therapy to allow translation and production of a modified dystrophin protein. Other potential therapeutic targets involve upregulation of compensatory proteins, reduction of the inflammatory cascade, and enhancement of muscle regeneration. So far, data from DMD clinical trials have shown limited success in delaying disease progression; unforeseen obstacles included immune response against the generated mini-dystrophin, inconsistent evidence of dystrophin production in muscle biopsies, and failure to demonstrate a significant improvement in the primary outcome measure, as defined by the 6-minute walk test in some studies. The long-term safety and efficacy of emerging treatments will depend on the selection of appropriate clinical end points and sensitive biomarkers to detect meaningful changes in disease progression. Correction of the underlying mutations using new gene-editing technologies and corticosteroid analogs with better safety profiles offers renewed hope for many individuals with DMD and their families. Keywords: Duchenne muscular dystrophy, emerging treatment, standard of care, review https://www.dovepress.com/current-and-emerging-treatment-strategies-for-duchenne-muscular-dystro-peer-reviewed-fulltext-article-NDTDuchenne muscular dystrophyemerging treatmentstandard of carereview |
| spellingShingle | Mah J Current and emerging treatment strategies for Duchenne muscular dystrophy Neuropsychiatric Disease and Treatment Duchenne muscular dystrophy emerging treatment standard of care review |
| title | Current and emerging treatment strategies for Duchenne muscular dystrophy |
| title_full | Current and emerging treatment strategies for Duchenne muscular dystrophy |
| title_fullStr | Current and emerging treatment strategies for Duchenne muscular dystrophy |
| title_full_unstemmed | Current and emerging treatment strategies for Duchenne muscular dystrophy |
| title_short | Current and emerging treatment strategies for Duchenne muscular dystrophy |
| title_sort | current and emerging treatment strategies for duchenne muscular dystrophy |
| topic | Duchenne muscular dystrophy emerging treatment standard of care review |
| url | https://www.dovepress.com/current-and-emerging-treatment-strategies-for-duchenne-muscular-dystro-peer-reviewed-fulltext-article-NDT |
| work_keys_str_mv | AT mahj currentandemergingtreatmentstrategiesforduchennemusculardystrophy |